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IMPROVED ONCOLYTIC VIROTHERAPY BY INCREASING VIRUS SPREAD WITHIN TUMORS 
Stephen Wechman 
December 17, 2014 
 
Oncolytic adenoviruses (Ads) have great therapeutic potential for lung cancer. 
Cancer selective E1b-deleted Ads are safe, however their efficacy remains 
limited clinically. To improve E1b-deleted Ads, Adhz60 was selected for greater 
anti-cancer efficacy by a process called bioselection, producing AdUV. AdUV 
preferentially lysed A549 and H1299 lung cancer cells more effectively than both 
the cancer selective Adhz60 and non-selective Ad5. AdUV induced greater LC3-
II expression, relative to LC3-I, indicating that AdUV (30.9-fold) induced 
autophagy more effectively than Ad5 (12.2-fold) and Adhz60 (7.8-fold) in A549 
cells. Mice treated with AdUV had significantly smaller tumors (p-value < 0.001) 
and prolonged survival (p-value = 0.0005) than mice treated with the negative 
control AdGFP. These results suggest that AdUV efficiently lyses lung cancer 
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The leading cause of death from cancer is lung cancer. The number of 
lung cancer deaths (159,260) in 2014 was comparable to the number of deaths 
(159,810) from the next four leading cancers combined: colon, breast, pancreatic, 
and prostate (American Cancer Society). The Surveillance Epidemiology and 
End Results (SEER) statistics indicate that the five-year survival rate of lung 
cancer patients improved from 11.4% in 1975 to 17.5% in 2006. Lung cancer will 
continue to be a leading cause of death unless more effective treatments are 
developed. 
Surgery is the best treatment option for early stage lung cancer. Lung 
cancer is staged using the Tumor Nodes Metastasis (TNM) system. Using this 
system, each patient is staged based upon the size of his/her primary tumor, 
lymph node involvement, and the presence or absence of distant metastasis [1]. 
Stage I lung tumors are less than 3 cm while stage II lung tumors are less than 7 
cm in size [1]. Neither stage I nor stage II lung tumors have invaded tissue 
beyond their primary site, therefore lobe resection is feasible for most stage I and 
stage II lung cancer patients [2]. When lung cancer is surgically resected, 85% of 
stage I and 77% of stage II cancer patients survive at least two years after 
treatment [3]. Surgically resected stage II lung cancer is also frequently treated 
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with adjuvant platinum-based chemotherapeutics [4]. Therefore, surgery remains 
the best treatment option for early stage lung cancer.  
For lung cancer patients beyond stage II, the combination of surgery, 
intravenous (IV) chemotherapy and radiation offer the best results clinically [5-7]. 
Stage III lung tumors are greater than 7 cm in size and have invaded one of the 
surrounding lung tissues such as the chest wall, pleura, or main bronchus [1]. 
Stage IV lung tumors can be of any size, however distant metastasis must be 
observed [1]. These distant metastases are frequently observed in the adrenal 
glands, bone, the opposite lung, liver or brain [8, 9]. The majority (57%) of lung 
cancer patients have distant metastases at the time of diagnosis. Therefore, 
most lung cancer patients are ineligible for surgery. Cancer chemotherapy has 
not significantly improved lung cancer patient survival despite the investigation of 
several different chemotherapeutic combinations clinically [10-12]. To treat lung 
cancer patients more effectively, novel cancer therapeutics and strategies are 
necessary.  
The use of cancer selective viruses or oncolytic virotherapy is an 
emerging lung cancer treatment [13, 14]. Oncolytic adenovirus (Ad) therapy is 
unique because Ads can spread within tumors following the initial infection of a 
small number of cancer cells [13, 15]. Cancer selective Ads are generated by the 
attenuation of viral genes such as by the deletion of E1b-19K and E1b-55K [16-
18]. ONYX-015 (dl1520) was the first cancer selective, E1b-55k deleted Ad 
studied clinically [19-21]. Many clinical trials studying E1b-deleted Ads have 
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recruited head and neck cancer patients as these tumors are accessible for 
intratumoral injection (IT). E1b-deleted Ads such as dl1520 displayed favorable 
characteristics during several preclinical and clinical studies [20-22]. A virus very 
similar to dl1520, H101, was approved commercially in China for cancer therapy 
in combination with the PF chemotherapy regimen (cisplatin and fluorouracil) by 
the China Food and Drug Administration (CFDA) [23]. In a phase III trial, H101 
treatment increased the tumor response rate in head and neck cancer patients 
treated with the PF regimen from 39.6% to 78.8% [24]. 
Ads are especially promising for the treatment of lung cancer. Ads have 
respiratory tropism, allowing them to very efficiently infect and therapeutically 
spread throughout the lung [25]. As a proof of concept, E1b-deleted Ads were 
shown to efficiently kill primary lung tumor cultures isolated at 0.1 multiplicity of 
infection (MOI) in vitro [26]. In a phase II clinical trial, Nemunaitis et. al. 
administered dl1520 intravenously (IV) at increasing doses to patients with 
metastatic lung cancer [27]. Their research revealed that dl1520 could infect and 
replicate within lung cancer patients tumors following IV injection. No serious 
side-effects were observed following dl1520 treatment [27]. Furthermore, Ads 
interact synergistically with cancer chemotherapy as shown in primary lung 
cancer tissue in vitro and lung cancer xenograft models in vivo [22, 26, 28]. 
Cheng et. al. and Chen et. al. also reported synergistic interactions when E1b-
deleted Ads were combined with rapamycin or indol-3-carbinol respectively in 
vitro [28, 29]. These studies indicate that adenovirus therapy is safe and 
cooperates with many cancer chemotherapeutics. 
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Multiple clinical trials have shown that Ads are safe and cancer selective, 
however their efficacy must be improved [19, 21, 23, 30, 31]. Bioselection can 
generate viruses with greater anti-cancer activity [32-34]. Bioselection typically 
entails the infection of cancer cells with viruses treated with mutagenic agents 
and reinoculated within cancer cell cultures. In this case, Adhz60 was treated 
with UV-light prior to the infection of the Ad-resistant Soas-2 cancer cells to 
select for more effective, cancer therapeutic Ads. Using bioselection, viruses with 
enhanced anti-cancer efficacy can be isolated without requiring a complete 
understanding of their virus-host interactions [32, 35]. By UV-irradiating Adhz60 
and reinoculation in Soas-2 Ad-resistant cancer cells, AdUV was isolated (Fig. 1). 
AdUV displayed greater anti-cancer efficacy than Adhz60 in all cancer cell lines 
tested. AdUV also induced autophagy more effectively than both Adhz60 and 
Ad5 in A549 cells. These results suggest that AdUV may be released from and 
spread between cancer cells very efficiently. In addition, AdUV significantly 
suppressed the growth of A549 xenograft tumors and prolonged the survival of 
athymic nu/nu mice. These studies have demonstrated the great therapeutic 











Figure 1. The bioselection process. Adhz60 was amplified in HEK293 cells 
prior to each cycle of UV-irradiation. Irradiated viruses (UVirrad) then infected the 
Ad replication-resistant Soas-2 cancer cells. Viruses were harvested once 
cytopathic effects (CPE) were observed in Soas-2 cells. Viruses harvested from 
Soas-2 cells were then amplified in HEK293 cells before subsequent cycles of 
UV irradiation and bioselection. After 72 cycles of bioselection, AdUV was 
isolated by plaque purification from a large plaque formed upon Soas-2 cells. 
Adhz60 was treated with 639 J/m2 UV type-C irradiation. UV-light was produced 











MATERIALS AND METHODS 
Cell lines and culture conditions  
HEK293 (ATCC no. CRL-1573) human embryonic kidney, MRC5 (ATCC 
no. CCL171) normal lung fibroblast, A549 (ATCC no. CCL-185) human lung 
carcinoma, H1299 (ATCC no. CRL-5803) metastatic human lung carcinoma of 
the lymph node, H441 (ATCC no. HTB-174) lung papillary adenocarcinoma, and 
MCF7 (ATCC no. HTB-22) human breast adenocarcinoma cells were all 
purchased from the American Type Culture Collection (Rockville, MD). A549, 
MCF7, MRC5 and HEK293 cells were maintained in Dulbecco’s Modified Eagle’s 
medium (DMEM). H1299 and H441 cells were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium. All cell culture media were supplemented with 
10% fetal bovine serum, L-glutamine, and penicillin/streptomycin (100 U/mL). All 
cells were cultured and maintained in humidified 5% CO2 incubators at 37oC. All 
cell culture reagents were obtained from VWR (VWR, Radnor, PA). 
Adenoviral vectors 
Wildtype adenovirus serotype 5 (Ad5, ATCC no. VR-5) was used as a 
non-selective Ad control. Adhz60 has a deletion of the entire E1b gene and 
promoter and was used as a cancer selective Ad control [36]. AdGFP is an Ad 
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vector with the entire E1 gene (E1a, and E1b) deleted which expresses green 
fluorescent protein (GFP) driven by the CMV promoter. AdGFP does not 
replicate nor induce cytopathetic effects (CPE) in infected cells [28]. AdUV was 
generated by a process known as bioselection as illustrated in Figure 1. UV-light 
was used to irradiate Adhz60 for 5 minutes, inactivating approximately 90% of 
virus particles. UV-light was produced by a germicidal lamp, USEG30T3 
(Sylvania, Danvers, MA), fitted with a 30 watt G30T8 UV-light bulb (Philips, 
Amsterdam, Netherlands) which produces UV type-C irradiation [37]. UV 
irradiation was measured with a model 25X UVX radiometer (Fisher Scientific, 
Waltham, MA). Using these conditions, 213 μW/cm2 UV type-C was produced, 
generating a total UV dose of 639 J/m2 after five minutes UV-irradiation (300 s). 
Irradiated viruses then used to infect Soas-2 cancer cells. Soas-2 cells do not 
support efficient Ad replication [38]. Ads were harvested from Soas-2 cells once 
CPE was observed. Harvested Ads were then amplified in HEK293 cells prior to 
subsequent UV-light irradiation. After 72 cycles of bioselection, viral clones were 
isolated by the plaque purification of large plaques formed on Soas-2 cells. The 
most active clone, AdUV, was used in this study. All Ad constructs are based on 
the Ad5 (wildtype) backbone sequence. 
Viral infection and titration  
Virus titer was determined using the infectious unit method as described 
previously [18, 39]. HEK293 cells were seeded overnight onto 96-well plates at a 
density of 1x103 cells per well and infected with virus samples serially diluted 
8 
 
tenfold. The presence or absence of CPE in HEK293 cells was recorded after a 
minimum of 7 days incubation at 37oC to calculate the virus titer or the number of 
virus particles per milliliter.  
To determine the virus release kinetics, A549 cells were seeded into 12-
well plates at a density of 1x105 cells per well. Each well was infected with one 
MOI of Ad5, Adhz60 or AdUV. Samples were collected at 6, 24, 36, 48, and 72 
hours post-infection. The cell culture media and cells were collected together. 
Virus infected cells were separated from the culture media by centrifugation 
using a micromax RF refrigerated microcentrifuge (Thermo Fisher Scientific, 
Waltham, MA) equipped with an IEC 851 rotor. Cells were centrifuged at 2,000 
RPM (350 RCF), at 4oC for five minutes. Media samples were then frozen at -
80oC, while cell pellets were resuspended in 1 mL of PBS and subjected to three 
freeze-thaw to release all virus particles into solution [28, 40]. Viral titers were 
then compared between Ad treatment groups by the number of virus particles 
inside (pellet) or outside (supernatant) of A549 cells. 
Western blot analysis  
A549 Cells were seeded at a density of 6x105 per 60 mm dish and treated 
as indicated. Cells were collected and centrifuged at 1,500 RPM (453 RCF) at 
4oC for five minutes in an eppendorf 15 amp 5810 R refrigerated centrifuged 
equipped with a A-4-62 rotor (Eppendorf, Hamburg, Germany). The cell pellets 
were then washed with phosphate buffered saline (PBS) to remove serum 
contained within the cell culture media prior to cell lysis with Radio immuno 
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precipitation assay (RIPA) buffer containing 50 mM Tris-HCl, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, and 0.1% sodium docecyl sulfate (SDS) with 
a protease inhibitor (PI) cocktail containing 4-(2-aminoethyl)-benzenesulfonyl 
fluoride (AEBSF), pepstatin A, L-trans-epoxysuccinyl-leucylamido(4-
guanidino)butane (E-64), bestatin, leupeptin, and aprotinin (10 mL/106 cells; 
Sigma, St. Louis, MO). Cell pellets were incubated on ice in PI containing RIPA 
buffer for 30 minutes and homogenized every 10 minutes using a vortex-genie 2 
to lyse cells (Scientific Industries, Bohemia, NY). Cell lysates were then 
centrifuged at 14,500 RPM (196,000 RCF) at 4oC for 10 minutes to remove cell 
debris from the lysate using a Micromax RF microcentrifuge equipped with an 
IEC 851 rotor (Thermo Fisher Scientific, Waltham, MA). The cell pellets were 
discarded while the supernatant was stored for further experimentation. The 
protein concentration of all lysates was determined using the Pierce BCA protein 
assay kit according to the manufacturer’s instructions (Thermo Fisher Scientific, 
Walton, MA). Equal amounts of cellular protein were resolved by electrophoresis 
through either 8% (E1A, hexon, penton, protein V, protein VI, protein VII) or 12% 
(LC3-I and LC3-II) SDS-polyacrylamide gels prior to transfer to Hybond-PVDF 
membranes activated with methanol (GE healthcare, Little Chalfont, UK) using a 
semi-dry transfer apparatus (BIO-RAD, Hercules, CA). Membranes were then 
blocked using 5% nonfat milk prepared in Tris-Buffered saline with Tween 20 
(TBST) for one hour at room temperature. To detect protein expression, 
membranes were incubated with the following primary antibodies: rabbit-anti-
adenovirus type 5 polyclonal antibody (1:10,000; abcam, Cambridge, England), 
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rabbit-anti-human LC3 monoclonal antibody (1:3,000; Novus Biologicals, Littleton, 
CO), rabbit-anti-human actin (1:2,000; Sigma, Saint Louis, MO) or mouse-anti-
adenovirus E1A antibody (1:1,000; BD Pharmagen, San Jose, CA) at 4oC on a 
lab-line thermal rocker overnight (Thermo Fisher Scientific, Waltham, MA). 
Primary antibody binding was detected by the incubation with the horse radish 
peroxidase (HRP) linked anti-mouse immunoglobin (Ig) or anti-rabbit Ig species-
specific whole antibodies diluted 1:5,000 for one hour at room temperature 
(Amersham, Piscataway, NJ). All antibodies were diluted in TBST. Enhanced 
chemiluminescence (ECL) reagents were used to detect HRP-linked secondary 
antibody binding according to the manufacturer’s instructions (Amersham, 
Piscataway, NJ). Light produced by the reaction of ECL and HRP was detected 
by exposure of membranes to CL-XPosure film 8 x 10 inches (Thermo Fisher 
Scientific, Waltham, MA) in an autoradiography cassette (Thermo Scientific, 
Pittsburgh, PA). Exposed films were then developed using a SRX-101A medical 
film processor according to the manufacturer instructions (Konica Minolta, Toyko, 
Japan). Developed films were then scanned using a Hewlett-Packard 4070 
Scanjet scanner (Hewlett-Packard, Palo Alto, CA). 
Plaque formation assay 
A549 cells were seeded into 6-well plates at a density of 6x105 per well. 
Cells were infected with Ad5, Adhz60 and AdUV at 0.01 MOI for 6 hours. The cell 
culture media were then removed and replaced with 5 mL of 1% nutrient agarose 
per well. The nutrient agarose was prepared by adding 1 g agarose (Fisher 
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Scientific, Waltham, MA) to 15 mL of double distilled water (ddH20). This solution 
was then autoclaved in a Getinge model 533LS vacuum steam sterilizer on a LQ-
15 cycle (Getinge, Lindholmen, Sweden). The agarose was then briefly reheated 
in a microwave on high for 30 to 45 seconds and mixed with 85 mL complete 
DMEM, the nutrient agarose medium was then equilibrated to approximately 
44oC prior to addition to cell monolayers. Images were taken six days post-
infection with an EVOS FL microscope (Life technologies, Carlsbad, CA) at 4X 
magnification. The pixel densities of ten representative plaques per Ad5, Adhz60 
and AdUV treatment groups were measured with the area density tool using Gel-
pro analyzer 4.0 software according to the manufacturer’s tutorial (Media 
cybernetics, Rockville, MD). The total number of pixels for each plaque was 
converted to millimeters (mm) by dividing the number of pixels per plaque by the 
number of pixels per one mm2. The pixel length of one mm (510 pixels) was 
determined by the 1,000 micrometer (µm) scale bar to yield the pixels per one 
mm2 of 260,100 pixels.  
Quantification of band intensity  
Band intensities were quantified by Gel-pro analyzer 4.0 software in 
accordance with the manufacturer’s tutorial (Media Cybernetics, Bethesda, MD). 
Densitometric values were expressed as the integrated optical density (IOD) for 
each band. These data were reported as the ratio of LC3-II/LC3-I with each LC3-I 
and LC3-II band normalized to their respective to actin bands [28]. Mock treated 
cells were represented as one-fold LC3-II/LC3-I expression. 
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Cytotoxicity assay  
Cells were seeded at a density of 2x104 (H1299), 3x104 (A549), 4x104 
(MCF-7) or 6x104 (H441) cells per well onto 24-well plates. Cytotoxicity was 
assessed by crystal violet staining [41]. Suspended cells were removed by 
aspiration and the remaining adherent cells were fixed with 3.7% formaldehyde 
for 20 minutes at room temperature. Excess formaldehyde was washed away 
with PBS and cells were stained using 1% crystal violet at room temperature for 
30 minutes. Excess crystal violet was washed away with water. Plates were then 
scanned using an HP Scanjet 4070 scanner (HP, Palo Alto, CA). The remaining 
crystal violet was then solubilized with a 2% sodium dodecyl sulfate (SDS) 
solution and the sample absorbances were measured at 590 nm using a Synergy 
HT Multi-Mode Microplate Reader (Bio-Tek, Winooski, VT). The absorbance (OD) 
values were then normalized to mock treated cells converting each sample OD 
into percent (%) cell viability by the formula, cell viability % = (OD of treated cells 
/ OD of Mock treated cells) x 100%.  
Lung cancer xenograft study  
Tumors were formed by the subcutaneous injection (SC) of 5x106 A549 
lung cancer cells into the right flank of athymic nu/nu mice. Palpable tumors were 
observed two weeks following SC injection. Once tumors reached 30 mm3, mice 
were randomized and treated by intratumoral injection (IT) with 5x108 plaque 
forming units (PFU) of either AdGFP or AdUV. Tumor volumes were calculated 
based upon the following equation, V = (L×W2)/2, where L is length and W is the 
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width of the tumor [40]. Both Ad treatments were suspended in 50 µL prior to IT 
injection. Mice were injected four times with 5x108 PFU of each treatment in three 
day intervals for a total dose of 2x109 PFU. Eight mice were treated with AdGFP 
and seven mice were treated with AdUV. All animals were handled humanely 
and all experiments were conducted using an approved IACUC protocol.  
DNA Sequencing  
DNA sequencing was performed at the University of Louisville KBRIN 
bioinformatics core facility using Ion PGM Sequencing 200 kit v2 and Ion PGM 
system. One Ion 314 v2 Chip was used for loading the enriched Ion One Touch 
200 ISP samples. Open source integrated genomics viewer (IGV) software was 
downloaded to view DNA sequence results. Mutations were considered to be 
present when the DNA was altered in greater than 95% of total reads for each 
gene region. Reading frames were observed using the translation track feature of 
IGV to determine if detected DNA mutations altered amino acid sequences. 
Statistical analysis  
All experiments were repeated at least three times. Quantification of 
results was reported as means of three independent experiments plus or minus 
(±) the standard deviation. The Pearson correlation coefficient (r) was used to 
evaluate the accuracy of equations used to calculate sample protein 
concentrations with the Pierce BCA protein assay kit. Statistical significance was 
assessed using analysis of variance analysis (ANOVA) and the Wilcoxon rank-
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sum test. Multiple comparisons of ANOVA tests were corrected using 
Bonferroni’s method. Multiple comparisons of Wilcoxon ranked-sum were 
corrected by Dunn’s test. Adjusted p-values are reported for each of these 
multiple comparisons. These statistical tests cannot report adjusted p-values 
greater than 1.0 or less than 0.0001. All statistical tests were conducted using 
GraphPad software (Microsoft, Redmond, WA). Detailed methods for the 
analysis of each dataset are provided as follows.  
Figures 3A-D were analyzed using two-way ANOVA to compare Adhz60 
versus Ad5 and Adhz60 versus AdUV treatment groups. Multiple comparisons 
were made between each virus dose or MOI. The EC50 of each virus which 
lysed treated cancer cells (Ad5, Adhz60 and AdUV) was also determined. First, 
values were expressed as the percent death rather than percent viability the virus 
dose was logarithmically transformed by the equation (x = log(x)). These data 
were then fit to their respective dose-response curves using log-agonist vs. 
normalized response regression analysis in Figure 3E. Considering AdUV had an 
EC50 of one MOI in A549 cells, a two-way ANOVA was used to observe if these 
data, Figure 3A-D, were significantly different at one MOI between all treatment 
groups and cell lines as tabulated in Figure 4F. Figures 4B and 5B were 
determined to have unequal variance between treatments groups by the Kruskal-
Wallis test. Therefore, Figures 4B and 5B were analyzed using the Wilcoxon 
rank-sum test. Multiple comparisons were made using Dunn’s test to determine if 
AdUV versus Ad5 and AdUV versus Adhz60 treatment groups were significantly 
different. Figure 8A was analyzed using two-way ANOVA to determine if tumor 
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growth following AdGFP and AdUV treatment was significantly different at each 
time-point (days). Figure 8C was analyzed using the Kaplan-Meijer Log-rank sum 
test to determine if the survival of mice following AdGFP and AdUV treatment 
was significantly different. These statistical tests were performed using 
GraphPad Prism software (Microsoft, Redmond, WA). Statistical significance was 







AdUV strongly destroys cancer cells.  
 AdUV was isolated by exposing Adhz60 to UV irradiation followed by 
selection in Ad-replication resistant Soas-2 cancer cells as illustrated in Figure 1. 
This process is called bioselection. The virus used for these studies, AdUV, was 
isolated from a large plaque formed on Soas-2 cells. The anti-cancer activity of 
AdUV was compared to the cancer non-selective wildtype Ad serotype 5 Ad5, the 
cancer selective E1b-deleted Ad Adhz60, and the E1a, E1b-deleted negative 
control Ad AdGFP. Ad5 and Adhz60 represent the positive and negative controls 
for MRC5 cell lysis respectively. H1299 human lung cancer and MRC5 normal 
lung cells were infected with AdGFP, Ad5, Adhz60, and AdUV at the indicated 
multiplicities of infection (MOI) for five days (Fig. 2A). AdUV induced greater 
cytopathic effect (CPE) than Adhz60 and Ad5 in H1299 lung cancer cells (Fig. 
2A). AdUV also killed MRC5 normal cells more effectively than Adhz60, however 
less than Ad5 at 10 MOI (Fig. 2A). Therefore to test if AdUV was cancer selective, 
MRC5 normal and H1299 lung cancer cells were treated at MOI 10 and observed 
for CPE (Fig. 2B). Ad5 induced CPE non-selectively in both normal lung and lung 
cancer cells, while Adhz60 only induced CPE in H1299 lung cancer cells as 
expected. AdUV induced less CPE in MRC5 normal cells at 10 MOI than Ad5, 
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however AdUV induced more CPE in H1299 lung cancer cells than both Ad5 and 
Adhz60 (Fig. 2A, B).   
 To study the oncolytic effects of AdUV further, A549, H1299, and H411 
lung cancer and MCF-7 breast cancer cells were treated with AdGFP, Ad5, 
Adhz60 or AdUV at the indicated MOIs for five days. The E1b-deleted Ad Adhz60 
was applied as a cancer selective control [36]. Therefore, Ad5 and AdUV were 
compared to Adhz60 to determine if Ad5 or AdUV displayed greater anti-cancer 
efficacy than Adhz60. Cell viability was determined via crystal violet staining and 
normalized to mock (0 MOI) treated cells (Fig. 3). Ad5 very effectively induced 
cancer cell death in all four cancer cell lines tested, whereas AdGFP did not alter 
cell viability (Fig. 2A-D). AdUV killed A549 lung cancer cells more effectively than 
both Adhz60 (p-value = 0.0002) and Ad5 (p-value = 0.005) at 0.3 MOI (Fig. 3A). 
AdUV also killed H1299 lung cancer cells more effectively than Ad5 (p-value < 
0.0001) and Adhz60 (p-value < 0.0001) at 0.3 MOI (Fig. 3B). Treatment with Ad5 
at one MOI was more effective than Adhz60 in H411 lung (p-value < 0.0001) and 
MCF-7 breast (p-value = 0.0009) cancer cells respectively. Ad5 and AdUV 
treatments were not significantly different in H441 and MCF7 cells (Fig. 3C-D). 
Adhz60 was significantly less effective than both Ad5 and AdUV in all cancer cell 
lines (Fig. 3A-D).  
 The viability of AdUV treated A549 cells was lower than Ad5 and Adhz60 
at all viral doses (MOI) tested. Therefore, studies investigated how AdUV killed 
A549 cells more effectively than Ad5. The EC50 values of Ad5, Adhz60 and 
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AdUV were determined for each cancer cell line (Fig. 3E). The EC50 of AdUV 
treated A549 cells was one MOI (0.99; Fig. 3E). Therefore, p-values were 
reported to determine if statistically significant differences were observed at one 
MOI between all Ads and cancer cell lines (Fig. 3F). These experiments taken 
together indicate that AdUV killed multiple cancer cell lines very efficiently with 
minimal effects upon MRC5 normal cells in vitro. 
AdUV displays greater viral release from cells. 
 AdUV was selected for the efficient lysis of and release from cancer cells 
during bioselection. Therefore, the plaque assay was used to study AdUV spread 
through A549 lung cancer cells. AdUV formed larger plaques than Ad5 (p-value = 
0.0248) and Adhz60 (p-value = 0.0002) in A549 cells (Fig. 4B). Larger plaque 
formation is indicative of more efficient cell lysis, release, and spread.  
 To study if the replication of AdUV was altered via bioselection, A549 cells 
were infected with Ad5, Adhz60 and AdUV at one MOI or the EC50 of AdUV (Fig. 
3A, E). A549 cells infected with AdUV displayed greater E1A expression than 
Adhz60 treated cells at 24 hours post-infection (Fig. 5A). A similar pattern was 
observed at 72 hours as AdUV infected cells had greater late protein expression 
than Adhz60 treated cells. Ad gene expression was not detected in the mock 
treatment group. 
 The concentration of Ad particles in the cell culture media was studied to 
determine if AdUV was released more efficiently from A549 cells than Ad5 and 
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Adhz60 at one MOI, 48 hours post-infection. Adhz60 titer was 0.4-fold and AdUV 
titer was 0.7-fold relative to Ad5 within the cell fraction of infected A549 cells. 
AdUV titer was 3.3-fold in the cell-free fraction which was significantly greater 
than Adhz60 (p-value = 0.02) which was 0.1-fold relative to Ad5 (Fig. 5B). These 
data indicate that AdUV was released from A549 cells more efficiently than 
Adhz60 but not Ad5.   
 To study the release kinetics of AdUV across time, A549 cells were 
infected with Ad5, Adhz60 or AdUV at one MOI. Virus samples were collected 
from these infected cells at 6, 24, 48, and 72 hours post-infection. Ad5 and AdUV 
virus production was similar inside of A549 cells while Adhz60 virus titer was 
slightly attenuated (Fig. 5C, left). The titer of AdUV was greater in the cell culture 
media than both Ad5 and Adhz60 (1.5x106 of Ad5, 1.5x105 of Adhz60, and 5x106 
of AdUV virus particles per ml at 48 hours) (Fig. 5C, right). AdUV was initially 
released from A549 cells at 36 hours post-infection (Fig. 5C, right). After 36 
hours AdUV virus release plateaued (Fig. 5C, right). Therefore, increased AdUV 
release from A549 cells may contribute to the formation of larger plaques.     
AdUV induces autophagy. 
Autophagy was investigated to determine if increased autophagy induction 
could explain the enhanced release and oncolysis phenotypes of AdUV. 
Autophagy involves the lysosomal recycling of cytoplasmic organelles and long 
lived proteins [48]. It has been reported that autophagy enhances Ad replication 
perhaps by increasing cellular energy and nutrition for the assembly for virus 
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particles [42]. During autophagy, LC3-I is produced by the cleavage of pro-LC3 
by the cysteine protease Atg4 into LC3-I [43, 44]. LC3-I matures into LC3-II by 
ATG3, ATG5, ATG7, and the ATG12-5 complex mediated conjugation of 
phosphatidylethanolamine (PE) to the LC3-I glycine amino acid [45]. Therefore, 
the LC3-II/LC3-I expression ratio was used to estimate autophagy induction and 
autophagosome abundance [45, 46]. While Ads are known to induce autophagy, 
it was necessary to confirm if AdUV induced LC3-II expression (Fig. 6A). AdUV 
treatment increased the LC3-II/LC3-I expression ratio by 2.0, 7.0, 9.1, and 13.6 
fold in A549 cells infected at 0.1, 0.3, 1, and 3 MOIs respectively (Fig. 6A). Thus, 
LC3-II/LC3-I cleavage increased in a dose dependent manner with AdUV dose 
(MOI). Then, one MOI was selected to observe if autophagy induction varied 
between AdGFP, Ad5, Adhz60 and AdUV treatment groups five days post-
infection. LC3-I conversion to LC3-II was detected in A549 cells treated with Ad5, 
Adhz60 and AdUV but not in the negative controls, mock or AdGFP, treatment 
groups (Fig. 6B). In this experiment, AdUV increased the LC3-II/LC3-I expression 
ratio 30.9 fold, greater than both Ad5 (12.2 fold) and Adhz60 (7.8 fold; Fig. 6B). 
A549 cells treated with one MOI of AdGFP, Ad5, Adhz60 or AdUV were 
photographed to observe changes in A549 cell morphology (400 x) three days 
post-infection. Cells treated with Ad5 and AdUV, but not AdGFP or Adhz60, 
displayed large cytoplasmic vesicles indicating autophagy activation 
morphologically at day three post-infection (Fig. 6C, arrowheads). These results 
indicate that AdUV induced autophagy more effectively than both Ad5 and 
Adhz60 in A549 cells. 
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Ion-torrent DNA sequencing of AdUV.  
 AdUV DNA was sequenced to identify mutations induced during 
bioselection [47]. Preliminary DNA sequencing revealed 31 mutations in the 
AdUV genome after sequence alignment to wildtype reference sequences (Fig. 7) 
[48]. Detailed analysis of mRNA open reading frames revealed that ten of these 
DNA mutations have altered at least one of their encoded amino acid residues 
(Fig. 7A). It is likely that some or all ten of these mutations are responsible for the 
oncolytic phenotype of AdUV (Fig. 7B). The mutation to pIII resulted in a non-
sense mutation, truncating twelve amino acids 559 – 571. Ad5 pIII has not been 
studied, however studies of Ad serotype 2 (Ad2) indicate that pIII is highly 
phosphorylated relative to other peptides in the Ad2 proteome [49]. Lind et. al. 
predicted twelve phosphorylation sites were present in Ad2: one tyrosine, one 
threonine and ten serines. The Ad2 phosphorylation site (503 – 519) on the 
carboxy-terminus indicates that perhaps AdUV has lost a phosphorylation site at 
its carboxy-terminus. Ad5 and Ad2 pIII peptides are each 571 amino acids long 
and have 98.6% sequence identity. Another mutation to Iva2 at position 4952 
changed the encoded glycine to an alanine. Iva2 is associated with virus 
packaging, thus mutation of Iva2 could lead to a possible mechanism of 
enhanced AdUV spread [50]. The mutation detected in pV at position 17387 
changed a glycine to an arginine. Glycine is hydrophobic with a single hydrogen 
atom as a side chain, however arginine has a six carbon nitrogenous side-chain 
with a positive charge at physiological pH. The endogenous function of pV is to 
bind Ad DNA to the capsid by interaction with p32 [51]. Therefore, the 
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substitution of a neutral glycine for the positively charged (basic) arginine, may 
allow pV to bind the negatively charged DNA sugar-phosphate backbone more 
effectively. AdUV surprisingly is E1b-wildtype in addition to these mutations. 
AdUV may have regained E1b via the homologous recombination with the E1 
region of HEK293 during bioselection [52]. These mutations likely increased the 
oncolytic efficacy of AdUV.  
AdUV inhibits tumor growth in nude mice 
DNA sequence analysis indicated that AdUV had regained the wildtype 
E1b gene, therefore the lethality and therapeutic efficacy of AdUV was tested in 
immunodeficient mice. The therapeutic effects of AdUV were evaluated using a 
human A549 lung cancer tumor xenograft nu/nu athymic mouse model. Once 
tumors reached 30 mm3 in size mice were randomized into the AdGFP and 
AdUV treatment groups. Mice were injected intratumorally (IT) with 5×108 plaque 
forming units (PFU) of AdGFP or AdUV prepared in 50 microliters (μL) of 
phosphate-buffered saline (PBS). Four injections were administered to mice from 
day six every three days until day fifteen. AdGFP was used as a negative control 
for these studies. The length and width of each tumor was measured using 
calipers every three days until day 125. Tumor volumes were calculated based 
upon the following equation, V = (L×W2)/2, where L is length and W is the width 
of each tumor [40]. Mice were euthanized once tumor volumes exceeded 1,000 
mm3. The tumor sizes between AdGFP and AdUV treatment groups reached 
statistical significance at day thirty-three (p-value = 0.0363, Fig. 8A). AdUV 
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treated tumors were significantly smaller (93.8%) than AdGFP treated tumors at 
day 51 (p-value < 0.0001, Fig. 8A). Representative photographs of treated mice 
indicated that AdUV strongly inhibited A549 tumor growth compared to AdGFP at 
day fifty-one (Fig. 8B). All seven mice treated with AdUV survived until day 125 
(p-value = 0.0005) while only two of eight total AdGFP treated mice survived (Fig. 
8C). Thus, AdUV treatment significantly improved the survival of A549 tumor-
bearing mice compared to the AdGFP treatment group. Of the seven mice 
treated with AdUV, two were tumor-free. The other five AdUV treated mice bore 
tumors which no longer grew but remained palpable until day 151. It is possible 
that AdUV was non-lethal in nude mice because human Ad replication is poor in 
murine relative to human cells. Therefore, AdUV may not be cancer selective in 
vivo. These results indicate that AdUV was safe and repressed A549 tumor 
















This study revealed the therapeutic potential of AdUV. AdUV was isolated 
following the UV-irradiation of the E1b-deleted Ad Adhz60 and selected in the 
Ad-resistant Soas-2 cancer cells during bioselection (Fig. 1) [36]. To my 
knowledge, this is the first time that bioselection has been used upon a cancer 
selective adenovirus (Ad). AdUV produced greater therapeutic effects than 
Adhz60 in all cancer cell lines tested. Focusing upon A549 lung cancer cells, the 
release of AdUV was greater than Adhz60 (p-value = 0.0204) but not Ad5 in vitro 
(Fig. 5B). The increased killing effects of AdUV may be related to greater 
autophagy induction in A549 cells (Fig. 6). Tumors treated with AdUV were 
significantly smaller than tumors treated with the negative control AdGFP (p-
value < 0.0001; Fig. 8A). The overall survival of AdUV treated mice was 
significantly greater than AdGFP treated mice (p-value = 0.0005; Fig. 8C). These 
data indicate that AdUV is a promising lung cancer therapeutic agent with no 
observed lethality to immunodeficient mice in vivo.  
Most of these mutations were located in the Ad structural genes. The 
absence of mutations to the early viral genes, such as E1 and E4, was surprising 
as these genes have important roles of an array of virus-host interactions. By far, 
cancer selective Ad research has focused primarily upon the modification of the 
Ad early genes by the deletion of E1b genes, E1b-19K and E1b-55K, or the 
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regulation of E1a gene expression using cancer-selective promoters [40, 53]. 
These results indicate that the late gene-encoded structural proteins may directly 
influence oncolytic Ad release and oncolysis. To study these mutations further, 
each mutation should be introduced into a well characterized Ad vector to 
understand their impact upon Ad replication and therapy.  
During bioselection AdUV regained E1b, likely via homologous 
recombination with the E1 sequences contained within HEK293 cells [52]. UV 
irradiation has been shown to enhance Ad recombination in vitro [54]. These 
results suggest that E1b may benefit Ad cancer therapy, even if E1b is not 
essential for Ads to replicate and lyse cancer cells [38]. E1b-deleted Ads are safe, 
however the mechanism of E1b-deleted Ad cancer selectivity has not been fully 
characterized [23, 55]. Previously, Zhang et. al. showed that Ad E1B-55K can 
induce the expression of the cell cycle-related genes, cyclin E and CDC25A [35]. 
The induction of cyclin E by E1B-55K was required for Ads to replicate in normal 
cells, but not in cancer cells which frequently have deregulated cyclin E 
expression [56]. The induction of cyclin E following Ad infection stimulates CDK2 
phosphorylation at the S612 during Ad infection [56]. Therefore, cyclin E 
deregulation in cancer cells may be an important target for the cancer selectivity 
of E1b-55K deleted Ads [38]. This study indicates that while E1b-deleted Ads are 
cancer selective they have limited efficacy, implicating the therapeutic potential of 
E1b-wildtype Ads as demonstrated in the literature [57, 58]. Thus, innovative 
strategies should be explored to develop more effective, cancer selective Ads.  
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The lethality of the E1b-wildtype AdUV was observed upon A549-tumor 
bearing in vivo. Mice were treated with the negative control AdGFP or the 
experimental AdUV. AdUV treated tumors were significantly smaller than AdGFP 
treated tumors at day fifty-one (p-value < 0.0001; Fig. 8A). Moreover, all seven 
AdUV treated mice survived while only two of the eight AdGFP treated mice 
survived until day 125 (p-value = 0.0005; Fig. 8B). No objective side-effects of 
AdUV treatment were observed. It is possible that AdUV is safe in mice because 
human Ad replication is poor in murine cells. These results indicate that AdUV 
may be therapeutic and safe in immunodeficient murine models.  
AdUV had greater efficacy than Adhz60 for the treatment of lung cancer 
cells in vitro and was therapeutically effective in vivo. AdUV displayed greater 
oncolytic efficacy in several cancer cell lines, producing larger plaques than Ad5 
(p-value = 0.0248) and Adhz60 (p-value = 0.0002) in A549 cells (Fig. 4B). AdUV 
was also a more effective autophagy inducer (30.9 fold) than both Ad5 (12.2 fold) 
and Adhz60 (7.8 fold) in A549 cells (Fig. 6B). It appears that the acquisition of 
E1b and/or mutations to the Ad late genes have increased the oncolytic potential 
of AdUV. Additional studies may be required to understand how these mutations 
affect Ad-mediated cancer cell lysis. These mutations should be recombined into 
an E1b-deleted cancer selective Ad vector to determine they are beneficial when 
incorporated into an E1b-deleted Ad background. Selective autophagy inducers 







Figure 2. The effect of AdUV upon normal lung and lung cancer cells. A) 
H1299 lung cancer or MRC5 normal lung cell lines were treated with the 
indicated MOIs of each adenovirus and stained with crystal violet after five days. 
B) The Cytopathic effects (CPE) of cells treated at 10 MOI were photographed. 
H1299 cells were photographed at day 3 post-infection. MRC5 cells were 




Figure 3. AdUV kills multiple cancer cell lines more effectively than Adhz60 
in vitro. A549, H1299, H441 lung cancer cells and MCF-7 breast cancer cells 
were treated with AdGFP, Ad5, Adhz60, or AdUV at the indicated MOIs. A-D) 
Cytotoxicity was determined by crystal violet staining after five days infection. 
Data was presented as the percent viability of treated cells relative to non-treated 
cells ± the standard deviation of three independent experiments. E) EC50 values 
were determined using GraphPad PRISM software. F) Two-way ANOVA with 
multiple comparisons were conducted between all Ad treatments in each cancer 
cell line at one MOI. All p-values were adjusted from two-way ANVOA analysis 
adjusted for post-hoc testing for multiple comparisons corrected by Bonferroni’s 
method. d.n.e. indicates the value does not exist, n.s. indicates a p-value > 0.05, 





Figure 4. AdUV spread in A549 cell monolayers. A) Two representative 
plaques of A549 cells treated with Ad5, Adhz60, and AdUV are shown. B) The 
number of pixels contained within ten representative plaques was determined 
and divided by the number of pixels per one mm2 to determine the size of each 
plaque in millimeters (mm2). These data were plotted as the average ± the 
standard deviation of ten plaques each (SD). Statistical significance was 
assessed using the Wilcoxon rank-sum test. Adjusted p-values were reported for 
multiple comparisons via Dunn’s test. n.s. indicates a p-value > 0.05, † indicates 






Figure 5. AdUV virus replication in A549 lung cancer cells. A) Ad protein 
production was observed at different time-points in A549 cells treated with one 
MOI of Ad5, Adhz60, or AdUV. B) Virus production inside and outside of A549 
infected cells at one MOI after 48 hours infection was normalized to the average 
Ad5 titer. Data is presented relative to Ad5 titer ± the standard deviation (SD) of 
three independent replicates. C) A549 cells were infected at one MOI and viral 
production was observed over time inside of and outside of infected A549 cells. 
Significance was determined via the Wilcoxon rank-sum test. Adjusted p-values 









Figure 6. AdUV induces greater autophagy in A549 lung cancer cells. A) 
A549 cells were infected with increasing MOIs of AdUV for five days. B) A549 
cells were treated with one MOI of AdGFP, Ad5, Adhz60 and AdUV for five days. 
A-B) LC3 expression was observed and the ratio of LC3-II to LC3-I was 
quantified relative to actin using Gel-pro analyzer 4.0 software. C) Images of 
A549 cells (400 x total magnification) treated with one MOI of AdGFP, Ad5, 
Adhz60 and AdUV were shown three days post-infection. Arrowheads indicate 






Figure 7. DNA sequencing of AdUV. A) A genetic map showing the location of 
mutations detected in AdUV relative to Ad5 wildtype sequences. The boxes 
indicate the Ad exons. B) Table of AdUV DNA mutations, their location, and 
changes to their amino acid sequences. The dark gray rows indicate alteration in 
the amino acid biochemical properties of encoded amino acid sequences. The 
dose of UV type-C (639 J/m2) irradiation was produced by a germicidal UV-lamp 










Figure 8. Treatment of xenograft tumors. Subcutaneous A549 tumor 
xenografts were grown following the subcutaneous injection (SC) of 5x106 A549 
cells in the right flank of nu/nu athymic mice. A) Tumors were injected 
intratumorally (IT) with AdGFP or AdUV once they reached 30 mm3 in size. Mice 
were treated by four IT injections from day six until day fifteen for a total dose of 
2x109 PFU. B) Representative mice treated with AdGFP and AdUV were 
photographed at day 51. Boxes indicate the magnified right flank of treated mice. 
C) Animals were sacrificed once tumors were greater than 1,000 m3 in size. 
Differences in tumor growth were assessed by two-way ANOVA with multiple 
comparisons between the AdGFP and AdUV treatment groups per day. P-values 
were adjusted via Bonferroni’s method. Differences in murine survival were 
determined using the Kaplan-Meier log-rank sum test. * indicates p-value < 0.05, 
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List of Abbreviations 
Ad  Adenovirus 
Ad2  Adenovirus serotype 2 
Ad5  Adenovirus serotype 5 
Ads  Adenoviruses 
AEBSF 4-(2-aminoethyl)-benzenesulfonyl fluoride 
ANOVA Analysis of Variance 
Atg  Autophagy related 
CFDA  China Food and Drug Administration 
ddH20  Double Distilled Water 
DMEM Dulbecco’s Modified Eagle Medium 
E1A  Early gene 1 A 
E1B  Early gene 1 B 
ECL  Enhanced Chemiluminescence 
FBS  Fetal Bovine Serum 
GFP  Green Fluorescent Protien 
HRP  Horse Radish Peroxidase 
Ig  immunoglobin 
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IGV  Integrated Genomics Viewer 
IT  Intratumoral injection  
IV  Intravenous injection 
LC3  Light Chain 3 
MOI  Multiplicity of Infection 
OD  Opitical Density or absorbance 
PBS  Phosphate Buffered Saline 
PFU  Plaque Forming Units 
PI  Protease Inhibitor 
RCF  Relative Centrifugal Force 
RIPA  Radioimmunoprecipitation Assay Buffer 
RPM  Revolutions Per Minute 
RPMI  Roswell Park Memorial Institute  
SC  Subcutaneous injection 
SDS  Sodium Dodecyl Sulfate 
SEER  Surveillance Epidemiology and End Results 
TBST  Tris-Buffered saline with Tween 20 
TNM  Tumor Nodes Metastatsis 









Curriculum Vitae January 2014 
505 South Hancock CTR Building, room# 452G 
Louisville, KY, 40202 
Phone #: (502) 316-0370 





2007 - 2011 B.S. in Biology, Georgetown College, Georgetown, KY 
2011 -  M.S. in Pharmacology and Toxicology, University of Louisville, Louisville, KY 
2011 -  Ph.D. in Pharmacology and Toxicology, University of Louisville, Louisville, KY 
 
ACADEMIC APPOINTMENTS  
2013 - 2014 Teaching Assistant  
  Department of Pharmacology and Toxicology  
  University of Louisville 
  Louisville, KY 
 
2011 -      Graduate Student Research Fellow  
  Department of Pharmacology and Toxicology  
  University of Louisville 
  Louisville, KY 
 
PROFESSIONAL MEMBERSHIPS AND ACTIVITIES   
 
2014 - American Association for Cancer Research 
2012 -  Kentucky Academy of Science 
2011 - 2012 Society of Toxicology 
            
 
HONORS AND AWARDS  
 
2014 2nd place Kentucky Academy of Sciences, Graduate Research presentation, University of 
Kentucky  
2014 2nd place Condict Moore research prize, James Graham Brown Cancer Center Retreat, 
University of Louisville 
2014 2nd place Research Louisville!, Masters Candidate, poster competition, University of 
Louisville 
2013     1st place Kentucky Academy of Science, Graduate Research, Morehead University 
2013 3rd place Research Louisville!, Masters Candidate, poster competition, University of 
Louisville 
2013 Featured in Georgetown College, “College to Career” publication, Georgetown College 
2011 Graduate Fellowship from the Integrated Programs in Biomedical Sciences (IPIBS), 
University of Louisville 
43 
 
2011 Top 15% worldwide, Mathematical Competition in Modeling, Georgetown College 
2010 Georgetown College Program for the Accelerated Learning in Sciences fellowship 
2003 Member, Honorable Order of Kentucky Colonels honor society 
2003 Eagle Scout award 
 
TEACHING ACTIVITIES 
University of Louisville (2013-present; all courses are team taught) 
 
2014 
 8/29 Patient SIM session “Pharmacology SIM Session on Autonomics” Medical 
 school students 
 4/12 Instructor, BIOL-395-01 “Cancer Chemotherapy: part 2 chemotherapy drugs” 
 Undergraduates 
 4/10 Instructor, BIOL-395-01 “Cancer Chemotherapy: part 1 cancer and the cell 
 cycle” Undergraduates 
 3/18 Instructor, BIOL-395-01 “Hormone Pharmacology: Androgens and 
 Estrogens” Undergraduate Students 
 
2013 
 11/18 Instructor, DHED-402-01 “Dental Pharmacology: Cancer Chemotherapy 
 Lecture” Dental Hygiene 
 4/16 Instructor, BIOL-395-01 “Cancer Chemotherapy: part 2 chemotherapy drugs” 
 Undergraduates 
 4/11 Instructor, BIOL-395-01 “Cancer Chemotherapy: part 1 cancer and the cell 
 cycle” Undergraduates 
 9/9 Patient SIM session “Pharmacology SIM Session on Autonomics” Medical 
 school students 
 Spring Teaching assistant, Supervised by Dr. Steven Myers for BIOL-395 Introduction  
 to pharmacology 
 




Title: Georgetown College Program for accelerated learning in the sciences (GC-PALS) 
Fellowship  
Role in Project: Undergraduate Researcher, Georgetown College  
Principal Investigator: Mark Christensen (Georgetown College) 
Funding Agency: Howard Hughes Medical Institute  
Project Period: May 3, 2010 to August 6, 2010  
Project Award: $4,000 (total) 
 
Title: Integrated Programs in Biomedical Sciences (IPIBS) Fellowship 
Role in Project: Graduate Student Researcher, University of Louisville 
Principal Investigator: Thomas Geoghegan (University of Louisville)  
Funding Agency:  University of Louisville 
Project Period: August 1, 2011 to June 1, 2013  








1.  Stephen Wechman, X. M. Rao, H. S. Zhou, Kelly McMasters. AdUV has greater 
potency, replication, and spread within lung cancer cells. University of Louisville. 
Kentucky Academy of Science at Moorhead University, Moorhead, Kentucky 
 
2.  Wechman, S.L., Rao X.M., McMasters K.M., Heshan, Z. 2014, Next generation oncolytic 
therapy is highly active against lung cancer. OVSOT Summer Meeting at the University of 
Louisville, Louisville, Kentucky.  
 
3. Wechman, S.L, Rao X. M., Gao H., McMasters K. M., Zhou, H., 2014. Viability of 
 losartan and other anti-fibrotics in combination with oncolytic adenovirus therapy. 




 Local/Regional Meetings 
 
1. Wechman, S.L., and Garcia-Ramos, G. 2011. Comparisons of inhibitory techniques 
against HIV-1 using recombinant viruses. Abstract for poster presentation, Kentucky 
Academy of Sciences Cellular and Molecular Biology section, Murray, KY. 
 
2.  Wechman, S.L., Rao, X.M., Cheng, P.H., Hao, H., Gomez-Gutierrez, J., McMasters, 
K.M., Heshan, Z. 2012. Insights from novel UV mutant oncolytic E1b-deleted 
adenoviruses for cancer gene therapy. Abstract for poster presentation, Research! 
Louisville, Louisville, KY. 
 
3. Wechman, S.L., Rao, X.M., McMasters, K.M., Heshan, Z. 2013. AdUV has greater 
potency, replication, and spread within lung cancer cells. Abstract for poster presentation, 
Research! Louisville, Louisville, KY. 
 
4. Wechman, S.L., Rao, X.M., McMasters, K.M., Heshan, Z. 2013. AdUV has greater 
potency, replication, and spread within lung cancer cells. Abstract for poster presentation, 
Brown Cancer Center Retreat, Louisville, Louisville, KY. 
 
5. Wechman, S.L., Rao, X.M., McMasters, K.M., Heshan, Z. 2014. AdUV has greater 
 potency, replication, and spread within lung cancer cells. Abstract for poster 
 presentation. Research Louisville, University of Louisville, Louisville, KY. 
 
6. Gao, H. Rao. X. M., Wechman. S. L., McMasters, K.M., Heshan, Z. 2014. Viability of 
 losartan and other anti-fibrotics in combination with oncolytic adenovirus therapy. 
 Abstract for poster presentation. Research Louisville, University of Louisville, 
 Louisville, KY. 
 
7. Wechman, S.L., Rao, X.M., McMasters, K.M., Heshan, Z. 2014. AdUV has greater 
 potency, replication, and spread within lung cancer cells. Abstract for poster presentation. 
 James Graham Brown Cancer Center Retreat, University of Louisville, Louisville, KY. 
 
8. Gao, H. Rao. X. M., Wechman. S. L., McMasters, K.M., Heshan, Z. 2014. Viability of 
 losartan and other anti-fibrotics in combination with oncolytic adenovirus therapy. 
 Abstract for poster presentation. James Graham Brown Cancer Center Retreat, 
 University of Louisville,  Louisville, KY. 
 
 
Manuscripts in progress 
 
1. Stephen L. Wechman, Pei-Hsin Cheng, Kelly M. McMasters, and H. Sam Zhou. Insights 




2.    Pei-Hsin Cheng, Stephen L. Wechman, Kelly M. McMasters, and H. Sam Zhou. 




1. Pei-Hsin Cheng, Xiao-Mei Rao, Stephen L. Wechman, Kelly M. McMasters, and H. Sam 
Zhou. Murine Lung Cancer Model Presenting Potential Clinical Challenges for Oncolytic 




1.  Interested in graduate school: Panel discussion for current Georgetown College 




MEMBER, Newtown Christian Church, Choir (2005-2011) 
MEMBER, Deacon, Newtown Christian Church (2010-2011) 
CHAIR, Head Deacon, Newtown Christian Church (2010) 
 
 
 
 
 
 
 
 
